Psychedelic drugs, once dismissed by some as a flashback to 1960s counterculture, have generated a resurgence of mainstream interest in the last few years. According to a study published by the National Institutes of Health, the use of psilocybin mushrooms has taken over as the predominant psychedelic in use globally since the 1970s, ahead of LSD. Will the use of psychedelics ever be universally accepted? Are stigmas associated with drug use and abuse curtailing important research on the true benefits and detriments of these substances? This conversation showcases the expertise of researchers, practitioners, and investors on the cutting edge of the use of psychedelics, and it offers innovative perspectives to help expand our minds and open up to the healing potential of these drugs.

Moderator

Tim Ferriss

Entrepreneur; Author, "Tools of Titans"

Speakers

Christian Angermayer

Founder, Apeiron Investment Group

Robin Carhart-Harris

Head, Centre for Psychedelic Research, Department of Brain Sciences, Imperial College London

Matthew Johnson

Principal Investigator, Associate Professor, Johns Hopkins Psychedelic Research Unit, Johns Hopkins University School of Medicine

Ayelet Waldman

Author, "A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life"